Loading…
Count Every Vote Act of 2007
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 7,255 other HR bills in the 110th — cohort avg 47d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2009 · third_quarter · Taxation/Internal Revenue Code
S. 1239 The New Markets Tax Credit Extension Act of 2007 H.R. 2075 The New Markets Tax Credit Extension Act of 2007 S. 1583 New Market Tax Credit Extension Act of 2008 H.R. 2628 New Market Tax Credit Extension Act of 2008
Client expense: Not reported · Firm income: Not reported
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2009 · third_quarter · Taxation/Internal Revenue Code
S. 1239 The New Markets Tax Credit Extension Act of 2007 H.R. 2075 The New Markets Tax Credit Extension Act of 2007 S. 1583 New Market Tax Credit Extension Act of 2008 H.R. 2628 New Market Tax Credit Extension Act of 2008
Client expense: Not reported · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2009 · third_quarter · Taxation/Internal Revenue Code
S. 1239 The New Markets Tax Credit Extension Act of 2007 H.R. 2075 The New Markets Tax Credit Extension Act of 2007 S. 1583 New Market Tax Credit Extension Act of 2008 H.R. 2628 New Market Tax Credit Extension Act of 2008
Client expense: Not reported · Firm income: $20,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2009 · third_quarter · Taxation/Internal Revenue Code
S. 1239 The New Markets Tax Credit Extension Act of 2007 H.R. 2075 The New Markets Tax Credit Extension Act of 2007 S. 1583 New Market Tax Credit Extension Act of 2008 H.R. 2628 New Market Tax Credit Extension Act of 2008
Client expense: Not reported · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2009 · third_quarter · Taxation/Internal Revenue Code
S. 1239 The New Markets Tax Credit Extension Act of 2007 H.R. 2075 The New Markets Tax Credit Extension Act of 2007 S. 1583 New Market Tax Credit Extension Act of 2008 H.R. 2628 New Market Tax Credit Extension Act of 2008
Client expense: Not reported · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2009 · second_quarter · Taxation/Internal Revenue Code
S. 1239 The New Markets Tax Credit Extension Act of 2007 H.R. 2075 The New Markets Tax Credit Extension Act of 2007 S. 1583 New Market Tax Credit Extension Act of 2008 H.R. 2628 New Market Tax Credit Extension Act of 2008
Client expense: Not reported · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2008 · fourth_quarter · Homeland Security
HR 6947/HR 2628/S 3181: FY2009 Appropriations for the Department of Homeland Security, Title III: Protection, Preparedness, Response, and Recovery; Title IV: Research and Development, Training, and Services, all provisions related to university-based research and training
Client expense: $50,000 · Firm income: Not reported
Government targets: Army, Dept of (Other), HOUSE OF REPRESENTATIVES, SENATE
2008 · third_quarter · Homeland Security
HR 6947/HR 2628/S 3181: FY2009 Appropriations for the Department of Homeland Security, Title III: Protection, Preparedness, Response, and Recovery; Title IV: Research and Development, Training, and Services, all provisions related to university-based research and training
Client expense: $90,000 · Firm income: Not reported
Government targets: Army, Dept of (Other), HOUSE OF REPRESENTATIVES, SENATE
2007 · year_end · Consumer Issues/Safety/Products
Drug Safety H.R. 3580; H.R. 2900 S. 1082 Livestock Cloning/Product Labeling H.R. 3161 S. 1859 H.R. 2764 H.R. 992 S. 414 H.R. 1396 S. 536 H.R. 4855 Drug Importation H.R. 3161 S. 1859 S. 1644 H.R. 2628 H.R. 2764 Animal Cloning Regulations Publication of FDA Draft Risk Assessment Study on Cloning of Livestock (H.R. 2419; H.R. 2764; H.R. 3161; S. 1859) Genetically Engineered (GE) Animals FDA and USDA Regulation of GE Animals Adventitious Presence U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
Client expense: $3,560,000 · Firm income: Not reported
2007 · year_end · Trade (domestic/foreign)
World Trade Organization on EU Biotech Moratorium U.S. Government Dispute Settlement Proceedings Foreign Agricultural Biotechnology Laws and Regulations U.S. Korea Free Trade Agreement China Biotechnology Regulations Mexico Biotech Regulations France Regulations of Plant Biotechnology Biosafety Protocol Implementation and Effect on Agricultural Biotechnology Possible U.S. Government Ratification U.S. Government Positions at Biosafety Protocol Meetings International Intellectual Property Enforcement Anti-counterfeiting ITC Exclusion Orders - Impact on Biotechnology Qualcomm Case CBD TRIPS Amendment Patent Disclosure Requirments Intellectual Property and Access to Medicines for Neglected Diseases and Diseases of Developing World Farm Subsidies in Trade H.R. 2720 Adventitious Presence U.S. Government Policy Position for Codex Guidelines on Adventitious Presence Restrictions on Importation of Plant Products/Lacey Act Amendments H.R. 1497 Drug Importation H.R. 3161 S. 1859 S. 1644 H.R. 2628 H.R. 2764
Client expense: $3,560,000 · Firm income: Not reported
2007 · year_end · Pharmacy
Medicaid Rebates H.R. 3162; H.R. 2764 S. 2499 Pharmaceutical Anti-Counterfeiting H.R. 3580; H.R. 2900 S. 1082 340B of the Public Health Service Act/Drug Prices for Covered Entitites Coverage of Different Entities S. 2499 Comparative Effectiveness Program Initiatives S. 2499 H.R. 3162; H.R. 2764; H.R. 976; H.R. 3963 Drug Importation H.R. 3161 S. 1859 S. 1644 H.R. 2628 H.R. 2764 Vaccines and Distribution/Shortage Issues H.R. 4991 S. 2456 Vaccines and Medicare Part B/Part D H.R. 4992
Client expense: $3,560,000 · Firm income: Not reported
2007 · year_end · Health Issues
Drug Safety H.R. 3580; H.R. 2900 S. 1082 Medicaid Rebates H.R. 3162 H.R. 2764 S. 2499 Comparative Effectiveness Program Initiatives H.R. 3162; H.R. 2764; H.R. 976; H.R. 3963 S. 2499 Stem Cell Research Drug Importation H.R. 3161 S. 1859 S. 1644 H.R. 2628 H.R. 2764 Funding for Food and Drug Administration (Critical Path Initiative; Human Drug Review) H.R. 3161 S. 1859 H.R. 2764 340B of the Public Health Service Act/Drug Prices for Covered Entitites Coverage of Different Entities S. 2499 FDA Regulatory Processes for First-Time Filers Food & Drug Administration Amendments Act/Food & Drug Administration Revitalization Act (H.R. 3580; H.R. 2900; S. 1082) User Fees/FDA Waivers for Small Businesses Risk Management Plans and Post-market Authorities Clinical Trial Registry and Results Databases Preemption Pharmaceutical Anti-Counterfeiting Priority Review Vouchers for Approved New Tropical Disease Therapies Civil Monetary Penalties FDA Advisory Panels/Conflict of Interest Possible Follow-on Biologics Amendments Follow-on Biologics H.R. 1038 H.R. 1956 S. 1695 S. 623 Presciption Drug User Fees H.R. 3580; H.R. 2900 S. 1082 Vaccines for Children Program H.R. 4990 Vaccines for Uninsured Adults H.R. 4993 National Vaccine Immunization Rates National Vaccine Program Office Working Paper on Adolescent Immunization Influenza Immunization Physician Quality Reporting Inititiative Vaccine Financing National Vaccine Program Office Draft White Paper on Vaccine Financing Vaccines and Medicare Part B/Part D H.R. 4992 Vaccines and Distribution/Shortage Issues H.R. 4991 S. 2456 Funding for Pandemic Influenza H.R. 3043 S. 1710 H.R. 2764 BARDA and Project BioShield HHS Implementation Plans Funding (H.R. 3043; S. 1710; H.R. 2764) Emerging Diseases Regulatory Processes Emergency Use Authorization Genetic Testing Regulatory Oversight Infectious Disease Research Tax Credit S. 2351 Funding for State Children's Health Insurance Program S. 2086; S. 1893; S. 2499 H.R. 3162; H.R. 3963; H.R. 976 Pharmaceutical Anti-Counterfeiting H.R. 3580; H.R. 2900 S. 1082 Erythropiesis Stimulating Agents CMS National Coverage Decision
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), UNDETERMINED, White House Office
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), UNDETERMINED, White House Office
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), UNDETERMINED, White House Office
Client expense: $3,560,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), UNDETERMINED, White House Office